BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.